October: A Month of Growth Despite Volatility Biases

Despite historically tinged investor reservations, October regularly proves to be a lucrative month for stocks. Three experts from Fool.com have now clearly identified promising growth stocks that should be acquired this month: Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. Eli Lilly is considered a leader in the growth sector of obesity. The company is significantly benefiting from its product Zepbound, whose sales are rapidly increasing. Additionally, Eli Lilly has reached a significant milestone with the approval of Kisunla, a therapy for Alzheimer's disease. The company continues to be innovative in the fields of cancer and immunotherapies, as well as diabetology. Older medications like Taltz and Verzenio also contribute steadily to revenue growth. Novo Nordisk, whose stock price has declined in recent months, now offers a promising opportunity for long-term investors. Rolled out internationally, Wegovy, a medication for weight reduction and cardiovascular risk reduction, could become a bestseller in the future. Although Ozempic continues to generate strong sales, the greatest potential lies in Wegovy, whose growth is impressive. At first glance, Vertex Pharmaceuticals may disappoint with a revenue growth of 'only' six percent in the second quarter. However, the focus should be on the pipeline: The gene therapy Casgevy and potential blockbusters like Vanzacaftor for cystic fibrosis are just the beginning. Promising are also the programs for kidney diseases and the hope to cure type 1 diabetes with VX-880 and VX-264.